/CNW/ - Today, AstraZeneca and Amgen announced the Canadian availability of Tezspire™ (tezepelumab injection), indicated for the add-on maintenance treatment.
Tezspire approved in Japan for the treatment of severe asthma astrazeneca.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from astrazeneca.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The .
First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations.
AstraZeneca s Tezspire has been recommended for marketing authorisation. | July 25, 2022